The quarter missed a high bar despite 31% growth. Total product revenue reached $118.1 million versus $90.1 million a year earlier, but came in below the published consensus of roughly $124.8 million; EPS of negative $0.07 also trailed expectations around negative $0.05 to negative $0.06.
| $ in millions, except EPS | Q2 2026 | Q2 2025 | YoY change | Published expectation |
|---|---|---|---|---|
| IBSRELA revenue | $86.2 | $65.0 | 33% | — |
| XPHOZAH revenue | $31.9 | $25.0 | 27% | — |
| Total product revenue | $118.1 | $90.1 | 31% | ~$124.8 |
| Net loss | $(16.7) | $(19.1) | 12% better | — |
| EPS | $(0.07) | $(0.08) | 13% better | ~$(0.05) to ~$(0.06) |
| R&D expenses | $26.1 | $15.7 | 67% | — |
| SG&A expenses | $101.4 | $84.0 | 21% | — |
(Financial Highlights)
The decisive issue is the IBSRELA outlook, not the reported growth. Ardelyx cut 2026 IBSRELA revenue guidance from $410–430 million to $350–370 million, a reduction of roughly 14% at the midpoint. Management cited payor requirements affecting new patient starts and access, meaning the problem is increasingly about prescription conversion and reimbursement friction rather than a lack of physician or patient demand. (Corporate Outlook; Commercial Update)
XPHOZAH remains a stabilizer, but not enough to offset the core downgrade. Q2 XPHOZAH revenue rose 27% to $31.9 million, with paid prescriptions up 25% and total dispenses up 33%. Its full-year revenue outlook of $110–120 million was reiterated, but that business is much smaller than IBSRELA and therefore cannot compensate for the lowered flagship-product trajectory. (XPHOZAH Commercial Update; Corporate Outlook)
The profitability path is still intact on paper, but the quality of the improvement is mixed. Operating expenses rose 28% year over year to $127.5 million, including a 67% increase in R&D, while the net loss narrowed to $16.7 million. Ardelyx lowered its 2026 operating-expense outlook from up to $520 million to below $500 million, which helps near-term cash control but also reflects a more cautious growth environment. Cash and investments were $281.8 million at June 30, including a $50 million debt drawdown, so the balance sheet is stronger than year-end but partly supported by additional borrowing. (Financial Highlights; Corporate Outlook)
Net read: operational momentum beat the prior-year comparison, but the reset to near-term expectations is materially worse. The unchanged long-term $1 billion IBSRELA ambition and reiterated XPHOZAH outlook preserve the broader story, yet the 2026 guidance cut signals that market-access headwinds will delay the revenue ramp and potentially the timing of the longer-term target. (Corporate Outlook)
Read the original 8-K on SEC EDGAR ↗